The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature

Rehman, Anees Ur; Hassali, Mohamed Azmi; Muhammad, Sohail Ayaz; Harun, Sabariah Noor; Shah, Shahid; Abbas, Sameen

doi:10.1007/s10198-019-01119-1

Cited by 62 publications

(54 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic diseases cause substantial economic burden and are major causes of morbidity and mortality (18)(19)(20). Two-third of the chronic disease patients are older than 60 years, suffer from different comorbidities, and are on polypharmacy (five or more drugs) (21).…”

Section: Introductionmentioning

confidence: 99%

Risk Factors Associated With Medication Errors Among Patients Suffering From Chronic Disorders

Rasool

Rehman

Imran

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Risk Factors Associated With Medication Errors Among Patients Suffering From Chronic Disorders

Rasool

Rehman

Imran

et al. 2020

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Work productivity loss and absenteeism affects the national economy. Indirect costs due to work loss and early retirement range between 20 and 69% of the total economic burden of COPD depending on the social security policies of the countries [18].…”

Section: Introductionmentioning

confidence: 99%

“…Most of the research on the pharmacoeconomics of COPD comes from Europe and the US [9,18]. Despite being a major health problem, existing data on the economic burden of COPD in Malaysia are limited.…”

Section: Introductionmentioning

confidence: 99%

Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study

Rehman

Hassali

Muhammad

et al. 2020

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) requires long-term pharmacological and non-pharmacological management that encompasses continuous economic burden on patients and society, and also results in productivity losses due to compromised quality of life. Among working-age patients, COPD is the 11th leading cause of work productivity loss. Objective The aim of this study was to assess the economic burden of COPD in Malaysia, including direct costs for the management of COPD and indirect costs due to productivity losses for COPD patients. Methodology Overall, 150 patients with an established diagnosis of COPD were followed-up for a period of 1 year from August 2018 to August 2019. An activity-based costing, 'bottom-up' approach was used to calculate direct costs, while indirect costs of patients were assessed using the Work Productivity and Activity Impairment Questionnaire. Results The mean annual per-patient direct cost for the management of COPD was calculated as US$506.92. The mean annual costs per patient in the management phase, emergency department visits, and hospital admissions were reported as US$395.65, US$86.4, and US$297.79, respectively; 31.66% of COPD patients visited the emergency department and 42.47% of COPD patients were admitted to the hospital due to exacerbation. The annual mean indirect cost per patient was calculated as US$1699.76. Productivity losses at the workplace were reported as 31.87% and activity limitations were reported as 17.42%. Conclusion Drugs and consumables costs were the main cost-driving factors in the management of COPD. The higher ratio of indirect cost to direct medical costs shows that therapeutic interventions aimed to prevent work productivity losses may reduce the economic burden of COPD.

show abstract

“…For the minimum price increase of 5%, 124,364, 125,712 and 22,070 excess COPD cases could be prevented over a 40-year period in Italy, England and Sweden, respectively, compared to the reference scenario. According to a recent systematic review 22 , the mean direct annual cost per COPD patient due to disease management in nine European countries is approximately 5700 euros. Using this cost value and assuming each patient lives 10 years with the disease, more than 7 billion euros could be saved in Italy and England, and over 1.2 billion euros in Sweden, if the COPD cases under the minimum price increase scenario were prevented over the 40-year study period.…”

Section: Discussionmentioning

confidence: 99%

“…These cost savings are certainly underestimates as indirect costs, such as loss in work productivity and early retirement costs, are not considered. When including the mean annual cost due to work productivity losses in Italy (397 euros) and Sweden (998 euros) (not reported for the United Kingdom) 22 to this annual cost of disease management, cost savings would rise to over 7.5 billion and over 1.4 billion euros in these two countries, respectively. Although these figures are only indicative, they provide a picture of the substantial cost savings that could be achieved with a relatively simple public health intervention of a one-time increase in tobacco price.…”

Section: Discussionmentioning

confidence: 99%

Health impact assessment to predict the impact of tobacco price increases on COPD burden in Italy, England and Sweden

Fuertes

Marcon

Potts

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Raising tobacco prices effectively reduces smoking, the main risk factor for chronic obstructive pulmonary disease (COPD). Using the Health Impact Assessment tool “DYNAMO-HIA”, this study quantified the reduction in COPD burden that would occur in Italy, England and Sweden over 40 years if tobacco prices were increased by 5%, 10% and 20% over current local prices, with larger increases considered in secondary analyses. A dynamic Markov-based multi-state simulation modelling approach estimated the effect of changes in smoking prevalence states and probabilities of transitioning between smoking states on future smoking prevalence, COPD burden and life expectancy in each country. Data inputs included demographics, smoking prevalences and behaviour and COPD burden from national data resources, large observational cohorts and datasets within DYNAMO-HIA. In the 20% price increase scenario, the cumulative number of COPD incident cases saved over 40 years was 479,059 and 479,302 in Italy and England (populous countries with higher smoking prevalences) and 83,694 in Sweden (smaller country with lower smoking prevalence). Gains in overall life expectancy ranged from 0.25 to 0.45 years for a 20 year-old. Increasing tobacco prices would reduce COPD burden and increase life expectancy through smoking behavior changes, with modest but important public health benefits observed in all three countries.

show abstract

The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature

Cited by 62 publications

References 42 publications

Risk Factors Associated With Medication Errors Among Patients Suffering From Chronic Disorders

Risk Factors Associated With Medication Errors Among Patients Suffering From Chronic Disorders

Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study

Health impact assessment to predict the impact of tobacco price increases on COPD burden in Italy, England and Sweden

Contact Info

Product

Resources

About